Australasian Brachytherapy Group

30th Annual
Scientific Meeting

25 - 27 February 2021
A Virtual Event

Register now

Brachytherapy vs Protons for Paediatric patient with Pelvic Cancer

The therapeutic advantage of proton therapy is well understood when compared to photon external beam treatments. However, there is minimal literature comparing the benefit of proton therapy when compared to brachytherapy. In particular for paediatric patients suffering from cancer to the pelvic region. Currently, such patients receive treatment using brachytherapy within Australia due to the lack of accessibility to proton therapy. In recent years, access to proton therapy has become more attainable. This study aims to prove that the current standard of brachytherapy treatment for paediatric patient with pelvic tumours remains superior.
Brachytherapy treatment is delivered via flexible implant tubes inserted during surgery at the Children’s Hospital Westmead. Treatment plans are optimised to deliver prescribed dose to the CTV whilst sparing near-by OARs, such a rectum and growth plates. Similarly, proton plans are optimised to deliver prescribed dose to the CTV whilst minimising entrance dose to near-by OAR using the research ProBeam machine data. The selection of entrance angles for proton therapy is crucial to help minimise dose to growth plates.
Preliminary results demonstrate that the brachytherapy dose distribution remains superior to proton plans due to eliminating the need for entrance dose and the rapid dose fall off of Ir-192.


Mrs Emma Sullivan Medical Physics Specialist, Crown Princess Mary Cancer Centre Westmead, Australia

Emma is a medical physics specialist who has a keen interest in brachytherapy, SRS and proton therapy treatments.